LifeMD’s (LFMD) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of LifeMD (NASDAQ:LFMD) in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a $12.00 price target on the stock.

LFMD has been the topic of several other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $15.00 target price on shares of LifeMD in a research note on Friday, September 20th. B. Riley began coverage on shares of LifeMD in a research report on Friday, August 23rd. They issued a “buy” rating and a $11.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, LifeMD has a consensus rating of “Buy” and a consensus target price of $12.00.

LifeMD Stock Performance

NASDAQ LFMD opened at $6.99 on Monday. The firm has a market cap of $302.74 million, a price-to-earnings ratio of -10.92 and a beta of 1.23. The company has a 50-day simple moving average of $4.95 and a two-hundred day simple moving average of $6.46. The company has a quick ratio of 0.78, a current ratio of 0.83 and a debt-to-equity ratio of 10.83. LifeMD has a 12-month low of $3.99 and a 12-month high of $12.88.

Hedge Funds Weigh In On LifeMD

Several hedge funds and other institutional investors have recently modified their holdings of LFMD. MetLife Investment Management LLC boosted its position in LifeMD by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 21,138 shares of the company’s stock valued at $111,000 after acquiring an additional 11,910 shares in the last quarter. Integrated Investment Consultants LLC bought a new stake in shares of LifeMD during the third quarter valued at approximately $129,000. Intech Investment Management LLC purchased a new stake in LifeMD in the third quarter worth $54,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in LifeMD by 6.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 765,916 shares of the company’s stock worth $4,013,000 after purchasing an additional 48,201 shares in the last quarter. Finally, Royce & Associates LP raised its holdings in LifeMD by 14.6% in the third quarter. Royce & Associates LP now owns 901,041 shares of the company’s stock worth $4,721,000 after purchasing an additional 114,710 shares in the last quarter. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.